阿托西班与利托君治疗前置胎盘出血的疗效及安全性对比

Comparison of efficacy and safety between atosiban and ritodrine for treatment of placenta previa complicated with hemorrhage

目的比较阿托西班与利托君治疗前置胎盘出血的临床疗效及安全性。方法选取80例前置胎盘产妇分为利托君组和阿托西班组,每组40例。利托君组患者给予静脉滴注利托君治疗,阿托西班组患者给予静脉滴注阿托西班治疗。观察比较两组患者症状缓解时间、治疗有效率、妊娠延长时间、产后出血量、不良反应和新生儿Apgar评分。结果阿托西班组治疗有效率为95.00%,高于利托君组的52.50%(P<0.05)。阿托西班组患者的症状缓解时间、产后出血量少于利托君组患者(P<0.05),妊娠延长时间、新生儿Apgar评分、胎儿体重长于或高于利托君组患者(P<0.05)。阿托西班组的不良反应发生率为8.3%,低于利托君组的40.0%(P<0.05)。结论阿托西班治疗前置胎盘出血的临床疗效优于利托君,其能更快缓解症状,降低不良反应发生率,优化新生儿围生结局。

Objective To compare the clinical efficacy and safety between atosiban and ritodrine for the treatment of placenta previa complicated with hemorrhage. Methods Eighty pregnant women with placenta previa were selected and divided into atosiban group and ritodrine group,with 40 cases in each group. The ritodrine group and atosiban group were intravenously administered ritodrine and atosiban respectively. The remission time of symptoms,therapeutic effective rate,time of prolonged pregnancy,puerperal blood loss,adverse reactions and neonatal Apgar score were observed and compared between the two groups. Results The therapeutic effective rate of the atosiban group was higher than that of the ritodrine group（95. 00% vs. 52. 50%; P〈0. 05）. The remission time of symptoms and puerperal blood loss in the atosiban group were less than those in the ritodrine group（P〈0. 05）. The time of prolonged pregnancy,neonatal Apgar score and natal weight in the atosiban group were longer or higher than those in the ritodrine group（P〈0. 05）. The incidence rate of adverse reactions in the atosiban group was lower than that in the ritodrine group（8. 3% vs. 40. 0%; P〈0. 05）. Conclusion The clinical efficacy of atosiban on placenta previa complicated with hemorrhage is superior to that of ritodrine. Atosiban can relieve symptoms more quickly,reduce the incidence rate of adverse reactions,and optimize the perinatal outcome of newborns.